Abstract
The UK’s COVID-19 epidemic during early 2020 was one of world’s largest and unusually well represented by virus genomic sampling. Here we reveal the fine-scale genetic lineage structure of this epidemic through analysis of 50,887 SARS-CoV-2 genomes, including 26,181 from the UK sampled throughout the country’s first wave of infection. Using large-scale phylogenetic analyses, combined with epidemiological and travel data, we quantify the size, spatio-temporal origins and persistence of genetically-distinct UK transmission lineages. Rapid fluctuations in virus importation rates resulted in >1000 lineages; those introduced prior to national lockdown were larger and more dispersed. Lineage importation and regional lineage diversity declined after lockdown, whilst lineage elimination was size-dependent. We discuss the implications of our genetic perspective on transmission dynamics for COVID-19 epidemiology and control.
Competing Interest Statement
KK is the founder of BlueDot, a social enterprise that develops digital technologies for public health. AW and IIB received employment or consulting income from BlueDot during this research.
Funding Statement
COG-UK is funded by the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. VH was supported by BBSRC grant BB/M010996/1; CR by a Fondation Botnar Research Award (Programme grant 6063) and UK Cystic Fibrosis Trust (Innovation Hub Award 001); JR by the UKRI GCRF One Health Poultry Hub (BB/S011269/1); MUGK by a Branco Weiss Fellowship and EU H2020 project MOOD; NRF by WT fellowship 204311/Z/16/Z and MRC-FAPESP awards MR/S0195/1 and 18/14389-0; TIV by a Branco Weiss Fellowship; IIB is funded by the Canadian Institutes for Health Research (02179 - 000); JTM, RMC, NJL and AR by WT Collaborators Award 206298/Z/17/Z; AR and ES by ERC grant 725422; DMA by NIHR Global Health Research Unit (16/136/111); OGP, MUGK, LDP and AEZ by the Oxford Martin School. AW and IIB received employment or consulting income from BlueDot during this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No such approval or exemption was necessary, as all data used are anonymised and publicly available.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ Full list of consortium names and affiliations are in Supplementary Material.
Data Availability
UK SARS-CoV-2 genomes and public metadata are available from www.cogconsortium.uk/data/ and deposited at gisaid.org and ENA (bioproject PRJEB37886). Non-UK genomes were obtained from gisaid.org. Raw data and analysis files for this work are in supplementary materials or available from GitHub at https://github.com/COG-UK/UK-lineage-dynamics-analysis, which also contains a list of sequence accession numbers. A GISAID acknowledgments table is available at https://github.com/COG-UK/UK-lineage-dynamics-analysis
